|
|
|
| Targeted Treatment of Hepatoma Using HSV-TK Suicide Gene with The PBI-SUR-TK Vector |
| ZHANG Ying-min1, ZHAO Na1, LI Yong-fang1, MENG Fan-xiu1, ZHANG Qi1, GAO Ran-peng1, ZHANG Yue-hong1, YU Bao-feng1, GUO Rui1, WANG Hai-long1, XIE Jun1, XU Jun2 |
1. Biochemistry and Molecular Biology, Shanxi Medical University, Taiyuan 030001, China;
2. Affiliated Tumor Hospital of Shanxi Medical University, Taiyuan 030013, China |
|
|
|
Abstract Objective:To construct a kind of expression vector which is cotrolled by survivin promoter, making a survivin promotor driving HSV-TK/GCV suicide gene system, and then detect its apoptosis inducing effect on HepG2 and HL-7702 cells. Methods:The study group synthesized a plasmid PBI-SUR-TK which contains TK gene, and transfect it into HepG2 and HL-7702 cells by liposome Lipofectanfine 2000.The HSV-TK gene expression by RT-PCR and the proteinlevel by Western blotting were detected. After adding GCV, CCK8 and flow cytometry were used to analyse the cell proliferation and apoptosis. Results:Contrasted with the control group, the HepG2 experimental group expressed more TK gene products, less proliferation and more apoptosis. There was no obvious difference between the HL-7702 groups. Conclusion:The HSV-TK/GCV suicide gene system driven by survivin promoter possibly has therapeutical effects on hepatoma.
|
|
Received: 13 August 2015
Published: 19 November 2015
|
|
|
|
Cite this article:
ZHANG Ying-min, ZHAO Na, LI Yong-fang, MENG Fan-xiu, ZHANG Qi, GAO Ran-peng, ZHANG Yue-hong, YU Bao-feng, GUO Rui, WANG Hai-long, XIE Jun, XU Jun. Targeted Treatment of Hepatoma Using HSV-TK Suicide Gene with The PBI-SUR-TK Vector. China Biotechnology, 2016, 36(2): 16-21.
URL:
https://manu60.magtech.com.cn/biotech/10.13523/j.cb.20160203 OR https://manu60.magtech.com.cn/biotech/Y2016/V36/I2/16
|
|
|
| [1] 杨成芳,徐庆.肝癌生物治疗的研究进展.医学综述,2013,18(4):524-527. Yang C F,Xu Q. Advances in research of biotherapies for primary hepatocellular carcinoma. Medical Recapitulate,2013,18(4):524-527.
[2] Yu B F,Wu J,Zhang Y,et al. Ultrasound-targeted HSVtk and Timp3 gene delivery for synergistically enhanced antitumor effects in hepatoma.Cancer Gene Ther,2013,20(5):290-297.
[3] 张悦红,高然朋,于保锋等.构建靶向性载脂蛋白E修饰脂质体介导的HSVtk/丙氧鸟苷系统.中国组织工程研究,2015,19(5):788-793. Zhang Y H,Gao R P,Yu B F,et al. Construction of targeting apolipoprotein E-modified liposome-mediated HSVtk/ganciclovir system. Chinese Journal of Tissue Engineering Research,2015,19(5):788-793.
[4] 王玉茹,童晓文. Survivin在宫颈癌中的研究进展.中华临床医师杂志,2014,8(6):1147-1150. Wang Y R,Tong X W. The research development of survivin in cervical cancer.Chin J Clinicians(Electronic Edition),2014,8(6):1147-1150.
[5] Niu J,Liu Z J,Song Y J,et al.Research on construction and identification of lentiviral vector of expressing miRNA targeting IGF1R gene regulated by surviving promoter and its inhibition to liver cancer cell growth.Chinese-German Journal of Clinical Oncology,2011,10(12):705-710.
[6] Hong S H,Zhang P,Zhang H,et al. Enforced effect of tk-MCP-1 fusion gene in ovarian cancer. Journal of Experimental & Clinical Cancer Research,2012,31(74):1-10.
[7] Zhou X L,Shi Y L,Li X. Inhibitory effects of the ultrasound-targeted microbubble destruction-mediated herpes simplex virus-thymidine kinase/ganciclovir system on ovarian cancer in mice.Experimental and Therapeutic Medicine,2014(8):1159-1163.
[8] Xiao J Y,Zhang G X,Qiu P X,et al.Tanshinone ⅡA increases the bystander effect of herpes simplex virus thymidine kinase/ganciclovir gene therapy via enhanced gap junctional intercellular communication. Plos One,2013,8(7):e67662.
[9] Marin V,Cribioli E,Philip B,et al. Comparison of different suicide-gene strategies for the safety improvement of genetically manipulated T cells.Human Gene Therapy Methods,2012,23:376-386.
[10] Casucci1 M,Perna S K,Falcone L,et al. Graft-versus-leukemia effect of HLA-haploidentical central-memory T-cells expanded with Leukemic APCs and modified with a suicide gene.The American Society of Gene & Cell Therapy,2013,21(2):466-475.
[11] Kim H A,Nam K,Lee M,et al. Hypoxia/hepatoma dual specific suicide gene expression plasmid delivery using bio-reducible polymer for hepatocellular carcinoma therapy. J Control Release,2013,171(1):1-10.
[12] Hu C X,Chen Z,Zhao W J,et al. Vesicular stomatitis virus G glycoprotein and ATRA enhanced bystander killing of chemoresistant leukemic cells by herpes simplex virus thymidine kinase/ganciclovir. Biomol Ther,2014,22(2):114-121.
[13] Yang J,Liu T J,Jiang Y X,et al.ATRA enhances the bystander effect of suicide gene therapy driven by the specific promoter LEP 503 in human lens epithelial cells. Molecular Vision,2012,18:2053-2066.
[14] Tian D W,Sun Y,Yang Y,et al.Human telomerase reverse-transcriptase promoter-controlled and herpes simplex virus thymidine kinase-armed adenoviruses for renal cell carcinoma treatment.Onco Targets and Therapy,2013,6:419-426.
[15] Higashi K,Hazama S,Araki A,et al. A novel cancer vaccine strategy with combined IL-18 and HSV-TK gene therapy driven by the hTERT promoter in a murine colorectal cancer model.International Journal of Oncology,2014,45:1412-1420.
[16] Akerstrom V,Chen C,Lan M S,et al. Adenoviral insulinoma-associated protein 1 promoter-driven suicide gene therapy with enhanced selectivity for treatment of neuroendocrine cancers. The Ochsner Journal,2013,13:91-99.
[17] 翟宏芳,崔大为,盛树海,等.Survivin siRNA沉默对非小细胞肺癌细胞生物学的影响.中华临床医师杂志,2014,8(10):1905-1909. Zhai H F,Cui D W,Sheng S H,et al. The biological effect of Survivin on NSCLC cell line by siRNA targeting Survivin. Chin J Clinicians,2014,8(10):1905-1909.
[18] Wang Z,Wang B M,Lou J F,et al. Mutation in fiber of adenovirus serotype 5 gene therapy vector decreases liver tropism. Int J Clin Exp Med,2014,7(12):4942-4950.
[19] Yao J,Zhang Y,Ramishetti S,et al. Turning an antiviral into an anticancer drug:nanoparticle delivery of acyclovir monophosphate. J Control Release,2013,170(3):414-420.
[20] Zhan Y,Yu B,Wang Z,et al. A fiber-modified adenovirus co-expressing HSV-TK and Coli.NTR enhances antitumor activities in breast cancer cells. Int J Clin Exp Pathol,2014,7(6):2850-2860. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
| |
Shared |
|
|
|
|
| |
Discussed |
|
|
|
|
